期刊论文详细信息
BMC Public Health
Can gender difference in prescription drug use be explained by gender-related morbidity?: a study on a Swedish population during 2006
Anders Halling3  Jan Sundquist4  Lars Borgquist1  Patrik Midlöv2  Jessica Skoog2 
[1] Department of Medical and Health Sciences, General Practice, Linköping University, SE-581 83 Linköping, Sweden;Department of Clinical Sciences in Malmö, Center for Primary Health Care Research, Lund University, SE-205 02 Malmö, Sweden;Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej 9A, DK-5000 Odense C, Denmark;Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA
关键词: Gender-related morbidity;    Gender difference;    Multi-morbidity;    Prescription drugs;   
Others  :  1131593
DOI  :  10.1186/1471-2458-14-329
 received in 2013-11-16, accepted in 2014-04-01,  发布年份 2014
PDF
【 摘 要 】

Background

It has been reported that there is a difference in drug prescription between males and females. Even after adjustment for multi-morbidity, females tend to use more prescription drugs compared to males. In this study, we wanted to analyse whether the gender difference in drug treatment could be explained by gender-related morbidity.

Methods

Data was collected on all individuals 20 years and older in the county of Östergötland in Sweden. The Johns Hopkins ACG Case-Mix System was used to calculate individual level of multi-morbidity. A report from the Swedish National Institute of Public Health using the WHO term DALY was the basis for gender-related morbidity. Prescription drugs used to treat diseases that mainly affect females were excluded from the analyses.

Results

The odds of having prescription drugs for males, compared to females, increased from 0.45 (95% confidence interval (CI) 0.44-0.46) to 0.82 (95% CI 0.81-0.83) after exclusion of prescription drugs that are used to treat diseases that mainly affect females.

Conclusion

Gender-related morbidity and the use of anti-conception drugs may explain a large part of the difference in prescription drug use between males and females but still there remains a difference between the genders at 18%. This implicates that it is of importance to take the gender-related morbidity into consideration, and to exclude anti-conception drugs, when performing studies regarding difference in drug use between the genders.

【 授权许可】

   
2014 Skoog et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150303010307569.pdf 159KB PDF download
【 参考文献 】
  • [1]Petrovic M, van der Cammen T, Onder G: Adverse drug reactions in older people: detection and prevention. Drugs Aging 2012, 29(6):453-462.
  • [2]Fastbom J: Increased consumption of drugs among the elderly results in greater risk of problems. Lakartidningen 2001, 98(14):1674-1679.
  • [3]Cascorbi I: Drug interactions–principles, examples and clinical consequences. Dtsch Arztebl Int 2012, 109(33–34):546-555. quiz 556
  • [4]Statistics prescription drugs expenses in Sweden in 2012 2012. http://www.ehalsomyndigheten.se/Documents/statistik/lakemedelsforsaljning_Q1Q2_2012.pdf webcite
  • [5]Anthony M, Lee KY, Bertram CT, Abarca J, Rehfeld RA, Malone DC, Freeman M, Woosley RL: Gender and age differences in medications dispensed from a national chain drugstore. J Womens Health (Larchmt) 2008, 17(5):735-743.
  • [6]Correa-de-Araujo R, Miller GE, Banthin JS, Trinh Y: Gender differences in drug use and expenditures in a privately insured population of older adults. J Womens Health (Larchmt) 2005, 14(1):73-81.
  • [7]Owens GM: Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm 2008, 14(3 Suppl):2-6.
  • [8]Bardel A, Wallander MA, Svardsudd K: Reported current use of prescription drugs and some of its determinants among 35 to 65-year-old women in mid-Sweden: A population-based study. J Clin Epidemiol 2000, 53(6):637-643.
  • [9]Roe CM, McNamara AM, Motheral BR: Use of chronic medications among a large, commercially-insured US population. Pharmacoepidemiol Drug Saf 2002, 11(4):301-309.
  • [10]Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW: Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. J Womens Health (Larchmt) 2008, 17(3):343-354.
  • [11]Fernandez-Liz E, Modamio P, Catalan A, Lastra CF, Rodriguez T, Marino EL: Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain. Br J Clin Pharmacol 2008, 65(3):407-417.
  • [12]Hofer-Duckelmann C: Gender and polypharmacotherapy in the elderly: a clinical challenge. Handb Exp Pharmacol 2012, 214:169-182. doi(214):169–182
  • [13]Redondo-Sendino A, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F: Gender differences in the utilization of health-care services among the older adult population of Spain. BMC Public Health 2006, 6:155. BioMed Central Full Text
  • [14]Dunnell K, Fitzpatrick J, Bunting J: Making use of official statistics in research on gender and health status: recent British data. Soc Sci Med 1999, 48(1):117-127.
  • [15]Schappert SM, Burt CW: Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat 2006, 159:1-66.
  • [16]Thorell K, Skoog J, Zielinski A, Borgquist L, Halling A: Licit prescription drug use in a Swedish population according to age, gender and socioeconomic status after adjusting for level of multi-morbidity. BMC Public Health 2012, 12:575-2458. BioMed Central Full Text
  • [17]Allebeck P, Moradi T, Jacobsson A: Sjukdomsbördan i Sverige och dess riskfaktorer. 2006. http://www.folkhalsomyndigheten.se/pagefiles/12245/A20064_dalys0606.pdf webcite
  • [18]The Swedish National Institue of Public Health: The National Bord of Health and Welfare. Folkhälsorapport 2012. 2012. http://www.fhi.se/PageFiles/14572/2012-3-6-Folkhalsan-i-Sverige-Arsrapport-2012.pdf webcite
  • [19]Animated population pyramids 1968–2010 2013. https://www.h5.scb.se/kommunfakta/pyramider/index.asp webcite
  • [20]Wirehn AB, Ostgren CJ, Carstensen JM: Age and gender differences in the impact of diabetes on the prevalence of ischemic heart disease: a population-based register study. Diabetes Res Clin Pract 2008, 79(3):497-502.
  • [21]Starfield B, Weiner J, Mumford L, Steinwachs D: Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 1991, 26(1):53-74.
  • [22]Zielinski A, Kronogard M, Lenhoff H, Halling A: Validation of ACG Case-mix for equitable resource allocation in Swedish primary health care. BMC Public Health 2009, 18(9):347-2458.
  • [23]Weiner JP, Starfield BH, Steinwachs DM, Mumford LM: Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991, 29(5):452-472.
  • [24]Orueta JF, Lopez-De-Munain J, Baez K, Aiarzaguena JM, Aranguren JI, Pedrero E: Application of the ambulatory care groups in the primary care of a European national health care system: does it work? Med Care 1999, 37(3):238-248.
  • [25]The World Health Organization 2011. http://www.whocc.no/atc/structure_and_principles/ webcite
  • [26]Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet 1997, 349(9063):1436-1442.
  • [27]Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global Burden of Disease Study. Lancet 1997, 349(9061):1269-1276.
  • [28]Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997, 349(9064):1498-1504.
  • [29]Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet 1997, 349(9062):1347-1352.
  • [30]Medical Products Agency, book of prescription drugs 2014. http://www.lakemedelsverket.se/english/ webcite
  • [31]Medical Products Agency, guidelines of treatment 2014. http://www.lakemedelsboken.se/ webcite
  • [32]U.S. Department of Health and Human Services National Institue of Health 2007. http://www.nih.gov/news/pr/apr2007/nhlbi-03.htm webcite
  • [33]Galdas PM, Cheater F, Marshall P: Men and health help-seeking behaviour: literature review. J Adv Nurs 2005, 49(6):616-623.
  • [34]Orzella L, Chini F, Giorgi Rossi P, Borgia P: Physician and patient characteristics associated with prescriptions and costs of drugs in the Lazio region of Italy. Health Policy 2010, 95(2–3):236-244.
  • [35]Weng SS, Chen YH, Lin CC, Keller JJ, Wang IT, Lin HC: Physician characteristics and prescription drug use during pregnancy: a population-based study. Ann Epidemiol 2013, 23(2):54-59.
  • [36]Glaeske G, Gerdau-Heitmann C, Hofel F, Schicktanz C: Gender-specific drug prescription in Germany“ results from prescriptions analyses. Handb Exp Pharmacol 2012, 214:149-167. doi(214):149–167
  • [37]Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC: Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013, 53(1):81-92.
  • [38]Piccinelli M, Wilkinson G: Gender differences in depression. Critical review. Br J Psychiatry 2000, 177:486-492.
  • [39]Riedel N, Fuks K, Hoffmann B, Weyers S, Siegrist J, Erbel R, Viehmann A, Stang A, Scheiner J, Dragano N: Insomnia and urban neighbourhood contexts--are associations modified by individual social characteristics and change of residence? Results from a population-based study using residential histories. BMC Public Health 2012, 12:810-2458. BioMed Central Full Text
  • [40]Woosley JA, Lichstein KL, Taylor DJ, Riedel BW, Bush AJ: Predictors of perceived sleep quality among men and women with insomnia. Behav Sleep Med 2012, 10(3):191-201.
  • [41]Ferguson JA: Prescribing practices and patient sex differences. J R Soc Health 1990, 110(2):45-49.
  文献评价指标  
  下载次数:5次 浏览次数:14次